(For practical recommendations and nightly live videos, check out Mr. Carter’s worthycharting.com.) Flat since November, biopharmaceutical company Insight is now emerging from a seven-month range in which it was stuck in a quagmire. We are buyers here with prices above $125. Two identical charts have their setups annotated in different ways. Either way, the message is a strong one. Disclosure: All opinions expressed by CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, its parent or affiliates, and may have been previously disseminated on television, radio, the Internet, or another medium. This content is provided for informational purposes only and does not constitute financial, investment, tax, or legal advice or a recommendation to purchase any securities or other financial assets. The Content is general in nature and does not reflect any individual’s unique personal circumstances. The above may not be appropriate for your particular situation. Before making any financial decisions, you should strongly consider seeking the advice of your own financial or investment advisor. Click here for full disclaimer.
